JP2020533373A - アレルギー性気道疾患（ａａｄ）／喘息の処置方法 - Google Patents

アレルギー性気道疾患（ａａｄ）／喘息の処置方法 Download PDF

Info

Publication number
JP2020533373A
JP2020533373A JP2020515070A JP2020515070A JP2020533373A JP 2020533373 A JP2020533373 A JP 2020533373A JP 2020515070 A JP2020515070 A JP 2020515070A JP 2020515070 A JP2020515070 A JP 2020515070A JP 2020533373 A JP2020533373 A JP 2020533373A
Authority
JP
Japan
Prior art keywords
mca
msc
asthma
cells
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533373A5 (enExample
Inventor
サムエル、クリシャン
ロイス、シモン
Original Assignee
サイナータ セラピューティクス リミテッド
サイナータ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903758A external-priority patent/AU2017903758A0/en
Application filed by サイナータ セラピューティクス リミテッド, サイナータ セラピューティクス リミテッド filed Critical サイナータ セラピューティクス リミテッド
Publication of JP2020533373A publication Critical patent/JP2020533373A/ja
Publication of JP2020533373A5 publication Critical patent/JP2020533373A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020515070A 2017-09-15 2018-08-31 アレルギー性気道疾患（ａａｄ）／喘息の処置方法 Pending JP2020533373A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903758A AU2017903758A0 (en) 2017-09-15 Method
AU2017903758 2017-09-15
PCT/AU2018/050937 WO2019051536A1 (en) 2017-09-15 2018-08-31 METHOD OF TREATING ALLERGIC RESPIRATORY TRACT DISEASE (DAA) / ASTHMA

Publications (2)

Publication Number Publication Date
JP2020533373A true JP2020533373A (ja) 2020-11-19
JP2020533373A5 JP2020533373A5 (enExample) 2021-10-14

Family

ID=65722228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515070A Pending JP2020533373A (ja) 2017-09-15 2018-08-31 アレルギー性気道疾患（ａａｄ）／喘息の処置方法

Country Status (14)

Country Link
US (1) US11471493B2 (enExample)
EP (1) EP3681519B1 (enExample)
JP (1) JP2020533373A (enExample)
KR (1) KR20200053501A (enExample)
CN (1) CN111093680A (enExample)
AR (1) AR112802A1 (enExample)
AU (1) AU2018333272B2 (enExample)
BR (1) BR112020004856A2 (enExample)
CA (1) CA3074470C (enExample)
ES (1) ES2996339T3 (enExample)
MX (1) MX2020002760A (enExample)
SG (1) SG11202001909TA (enExample)
TW (1) TWI806896B (enExample)
WO (1) WO2019051536A1 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) * 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
AU2011343736A1 (en) * 2010-12-17 2013-05-02 Anthrogenesis Corporation Treatment of immune-related diseases and disorders using amnion derived adherent cells
RU2018128383A (ru) * 2012-03-07 2019-03-14 Янссен Байотек, Инк. Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
US20150064141A1 (en) * 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
WO2013159091A2 (en) * 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Mirna modulators of thermogenesis
CN104471059B (zh) * 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
ES2813407T3 (es) * 2012-08-06 2021-03-23 Brainstorm Cell Therapeutics Ltd Métodos para generar células madre mesenquimales que secretan factores neurotróficos
EP2931373B1 (en) * 2012-12-12 2019-08-21 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
CA3141731A1 (en) 2013-03-13 2014-10-09 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
EP3233097A4 (en) * 2014-12-19 2018-08-08 Cell Ideas Pty Ltd. Improved cell therapies
CA3017772C (en) 2016-03-16 2023-02-21 Cynata Therapeutics Limited Colony forming medium and use thereof
WO2018023170A1 (en) * 2016-08-04 2018-02-08 Hudson Institute of Medical Research A method of treatment
AU2018285953A1 (en) 2017-06-16 2020-01-16 Cynata Therapeutics Limited Method for treating a side effect of immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROYCE SG: "Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fi", FASEB J, JPN6022026871, 16 June 2017 (2017-06-16), pages 4168 - 4178, ISSN: 0004955649 *

Also Published As

Publication number Publication date
RU2020111190A3 (enExample) 2022-03-30
KR20200053501A (ko) 2020-05-18
CN111093680A (zh) 2020-05-01
TWI806896B (zh) 2023-07-01
AU2018333272A1 (en) 2020-03-05
AU2018333272B2 (en) 2022-12-08
EP3681519C0 (en) 2024-10-30
SG11202001909TA (en) 2020-04-29
EP3681519B1 (en) 2024-10-30
ES2996339T3 (en) 2025-02-12
US11471493B2 (en) 2022-10-18
RU2020111190A (ru) 2021-10-15
MX2020002760A (es) 2020-07-20
CA3074470A1 (en) 2019-03-21
US20200276243A1 (en) 2020-09-03
EP3681519A4 (en) 2021-04-28
WO2019051536A1 (en) 2019-03-21
AR112802A1 (es) 2019-12-11
TW201919666A (zh) 2019-06-01
BR112020004856A2 (pt) 2020-09-15
EP3681519A1 (en) 2020-07-22
CA3074470C (en) 2024-01-16

Similar Documents

Publication Publication Date Title
Chu et al. Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly
JP6633056B2 (ja) 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
JP6967228B2 (ja) 治療方法
Profita et al. β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD
KR20110036101A (ko) 조합된 치료를 사용한 안과질환 및 과도한 혈관신생의 치료
Li et al. Critical role of alternative M2 skewing in miR-155 deletion-mediated protection of colitis
US20130101553A1 (en) Inducing inactivation of fibrogenic myofibroblasts
JP2019532634A (ja) 肝損傷の処置における使用のためのマクロファージに基づく治療法
Ikhapoh et al. Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells
Byun et al. Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice
JP2005514406A (ja) 疾患および損傷の処置のための一酸化窒素ドナー
US20210069177A1 (en) Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof
JP2020533373A (ja) アレルギー性気道疾患（ａａｄ）／喘息の処置方法
RU2790031C2 (ru) Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы
HK40024451B (en) Method for treating allergic airways disease (aad)/ asthma
HK40024451A (en) Method for treating allergic airways disease (aad)/ asthma
US20230218572A1 (en) Compositions and methods for improved mesenchymal stem cell therapy
EP3873503B1 (en) Treatment of cachexia using fibroblast cells and products thereof
CN113069472B (zh) 肝脏前体细胞、其制备方法以及在抑郁症治疗中的用途
Gerganova Inflammatory mechanisms after ischaemic stroke: characterisation of central nervous system (CNS) border-associated macrophages (BAMs) and dimethylarginine dimethylaminohydrolase (DDAH2)
Azari et al. The use of Wharton's jelly-derived mesenchymal stem cells to accelerate second-intention cutaneous wound healing in goat.
HK40116423A (en) Treatment of cachexia using fibroblast cells and products thereof
JP2025504662A (ja) 脊髄損傷の治療のための組成物及び方法
Dharmarajan Regulation of gliosis in the mouse retina
Caliari-Oliveira et al. CT-1389 Accepted 05/01/2015 for publication in “Cell Transplantation”

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230104